

PERSONAL INFORMATION



Corrado Barbui, MD

 Section of Psychiatry, Ospedale Policlinico GB Rossi, Piazzale Scuro 10, Verona, Italy

 +39 045 812 6418

 corrado.barbui@univr.it

Sex Male | Date of birth  | Nationality Italian

CURRENT POSITION

- 2015 – Present **Full Professor of Psychiatry**
University of Verona, Italy
- 2013 – Present **Director, *WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation***
University of Verona, Italy

WORK EXPERIENCE

- 2012 – Present **Clinical Team Leader**
Azienda Ospedaliera Universitaria Integrata di Verona, Italy
- 2011 – 2014 **Associate Professor of Psychiatry**
University of Verona, Italy
- 2002 – 2010 **Lecturer in Psychiatry**
University of Verona, Italy
- 2000 – 2001 **Researcher**
Head, Laboratory of Epidemiology and Social Psychiatry, Mario Negri Institute for Pharmacological Research, Milan, Italy
- 1998-1999 **Visiting Scholar**
Section of Epidemiology and General Practice, Institute of Psychiatry, King's College, London, UK

EDUCATION AND TRAINING

- 2000 Qualification as Psychiatrist
- 1997 Qualification as Specialist in Pharmacological Research, Mario Negri Institute for Pharmacological Research, Milan, Italy
- 1993 Qualification as Medical Doctor (MD).

ADDITIONAL INFORMATION

- 2015 – Present **Editor-in-Chief, *Epidemiology and Psychiatric Sciences***
(<http://journals.cambridge.org/action/displayJournal?jid=EPS>)
- 2013 – Present Inclusion in the list of the Top Italian Scientists – based on the h-index score
(<http://www.topitalianscientists.org>)

2002 – Present **Editor**, Cochrane Collaboration Depression Anxiety and Neurosis Group - Cochrane Collaboration (<https://www.cochrane.org>)

Publications Professor Corrado Barbui published so far **over 300 full papers** in international scientific Journals. A list of Professor Corrado Barbui scientific contributions can be accessed at: <http://scholar.google.it/citations?user=xloo8tMAAAAJ>

Citations (GOOGLE SCHOLAR): 11636 (lifetime); 7654 (last five years)
h-index (GOOGLE SCHOLAR): **53 (lifetime)**; 39 (last five years)
i10-index (GOOGLE SCHOLAR): 173 (lifetime); 132 (last five years)

Selection of 5 best publications

Barbui C, Bighelli I. Regulatory science in Europe: the case of schizophrenia trials. *Lancet* 382, 1234-1235, 2013.

Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new generation antidepressants: a multiple-treatments meta-analysis. *Lancet* 373, 746–58, 2009.

Barbui C, Dua T, van Ommeren M, Yasamy MT, Fleischmann A, Clark N, Thornicroft G, Hill S, Saxena S. Challenges in Developing Evidence-Based Recommendations Using the GRADE Approach: The Case of Mental, Neurological, and Substance Use Disorders. *PLOS Medicine* 7, e1000322, 2010.

Reid S, Barbui C. Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants. *BMJ* 340, c1468-1472, 2010.

Furukawa TA, McGuire H, Barbui C. Meta-analysis of effects and side-effects of low-dosage tricyclic antidepressants in depression. *BMJ* 325, 991-999, 2002.

Selection of 5 publications relevant to this call

Koesters M, Ostuzzi G, Barbui C. Vortioxetine for depression in adults [Protocol]. *Cochrane Database of Systematic Reviews* 2015, Issue 2. Art. No.: CD011520. DOI: 10.1002/14651858.CD011520.

Pringsheim T, Kelly M, Barbui C. Stopping antidepressants following depression. *BMJ*, 18; 352: i220, 2016.

Reid S, Barbui C. Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants. *BMJ*, 340, c1468-1472, 2010.

Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new generation antidepressants: a multiple-treatments meta-analysis. *Lancet*, 373, 746–58, 2009.

Furukawa TA, McGuire H, Barbui C. Meta-analysis of effects and side-effects of low-dosage tricyclic antidepressants in depression. *BMJ*, 325, 991-999, 2002

Selection of the 5 latest publications

Bighelli I, Trespici C, Castellazzi M, Cipriani A, Furukawa TA, Girlanda F, Guaiana G, Koesters M, Barbui C. Antidepressants and benzodiazepines for panic disorder in adults. *Cochrane Database of Systematic Reviews* 9: CD011567, 2016.

Barbui C, Dua T, Kolappa K, Saraceno B, Saxena S. Access to psychotropic medicines in low-resource settings. *Lancet Psychiatry* 3(10), 913-915, 2016.

Dua T, Barbui C, Patel AA, Centeno Tablante E, Thornicroft G, Saxena S, WHO's mhGAP Guideline team. Discussion of the updated WHO recommendations for mental, neurological, and substance-use disorders. *Lancet Psychiatry* 3, 1008-1012, 2016.

Saraceno B, Barbui C. Global mental health: achievements, concerns and (unanswered) questions. *Epidemiology and Psychiatric Sciences* 25, 493-494, 2016.

Nosè M, Bighelli I, Castellazzi M, Martinotti G, Carrà G, Lucii C, Ostuzzi G, Sozzi F, Barbui C. Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-

sectional multicentre study. *Epidemiology and Psychiatric Sciences* 25, 532-540, 2016.

Book Chapters

Saraceno B, Terzian E, Montero-Barquero F, Tognoni G, Barbui C. Salud mental en el nivel primario de atención: Estudio en una muestra de pacientes en seis países centroamericanos. *Organizacion Panamericana de La Salud*, World Health Organisation, 1995.

Cipriani A, Barbui C, Baethge C, Wilder H, Geddes J. Antidepressive Monotherapie. In: Bauer M, Berghofer A, Adli M (eds). *Akute und Therapieresistente Depressionen*. Springer Verlag: Heidelberg, pages 185-193, 2005.

Barbui C, Cipriani A, Tansella M. Beneficial and Adverse Effects of Antidepressants on Suicide Mortality in Individuals with Major Depression. In: *Suicide in Psychiatric Disorders*. Editors: R. Tatarelli, M. Pompili, P. Girardi. In press. Nova Science Publishers, Inc; 19-36, 2007.

Barbui C, Tansella M. La identificación y tratamiento de la enfermedad mental en atención primaria: el caso de la depresión. In *Psiquiatria en Atención Primaria*, 2nd Ed. (ed. J.L. Vazquez-Barquero), Aula Medica Ediciones: Madrid, 809-819, 2007.

Cipriani A, Barbui C. Understanding and using systematic literature reviews. In: *Oxford Textbook of Community Mental Health*. Eds: G Thornicroft, G Szmukler, KT Mueser, RE Drake. Oxford University Press: 2011.

Cipriani A, Nosè M, Barbui C. Psychotropic drug epidemiology and systematic reviews of randomised clinical trials: The roads travelled, the roads ahead in *“Improving Mental Health Care: The Global Challenge”*, Graham Thornicroft, Mirella Ruggeri, David Goldberg, ed Wiley-Blackwell, pag 319-340: 2013.

Books

Martini N, Bonati M, Pandolfini C, Raschitelli N, Rossi LM, Farina LM, Bacis G, Grandori L, Zanfi D, Miselli M, Rocchi F, Barbui C, Bianchi M, Chiodini B, D'Avanzo B, Damia G, Martinoli E, Monesi L, Riva E, Roncaglioni MC, Schiavetti B, Clavenna A, Latini R, Nobili A, Zuccato E. *Guida all'uso dei farmaci per i bambini*. Ministero della Salute, Direzione Generale della Valutazione dei Medicinali e della Farmacovigilanza. Istituto Poligrafico e Zecca dello Stato S.p.A. Roma: 2003.

Barbui C, Cipriani A, Saxena S. *Pharmacological treatment of mental disorders in primary health care*. WHO Press, 2009. World health Organization, Geneva.

Barbui C, Bighelli I, Nosè M, Ostuzzi G, Purgato M e Gruppo di Lavoro del Dipartimento Interaziendale di Salute Mentale Verona *Uso degli Psicofarmaci in Situazioni Cliniche Complesse. Raccomandazioni GRADE* (2014). Il Pensiero Scientifico Editore: Roma, 2014.

World Health Organization and Calouste Gulbenkian Foundation. Improving access to and appropriate use of medicines for mental disorders. Geneva, World Health Organization, 2016.

Selected Grants

1996 - Consiglio Nazionale delle Ricerche, Roma, Grant n. 201.12.78, Codice n. 12.00.41: Progetto Finalizzato *“Invecchiamento e Qualità della Vita, Aspetti Epidemiologici e Meccanismi Patogenetici”*.

1997 - Agreement for Performance of Work, World Health Organisation (WHO). GL GLO MNH 042 VP 96.999: *‘The Rational Use of Psychotropic Drugs’*.

2001 - Agreement for Performance of Work, World Health Organisation (WHO) GL GLO MNH 348 XE 00.J: *‘Improving Access to Essential Psychotropic Drugs in Developing Countries’*. WHO Geneva Switzerland.

2003 - Agreement for Performance of Work, World Health Organisation (WHO) GLGLOMNH166XK02: *“ATLAS – Psychotropics: improving psychotropic drug availability”*.

in the world". WHO Geneva Switzerland.

2003 - Ministero della Salute, Direzione Generale della Valutazione dei Medicinali e della Farmacovigilanza, Roma: *"Monitoraggio delle prescrizioni di farmaci antipsicotici e antidepressivi nell'attività territoriale e ospedaliera dei servizi psichiatrici"*.

2006 - Sperimentazione Multicentrica Nazionale Randomizzata denominata Studio LAST-RD: "Lithium And Standard Therapy in Resistant Depression. An independent, pragmatic, multicentre, parallel-group, superiority trial".

2010 - Cochrane review of implementation of treatment guidelines for specialist mental health care. Ammesso al finanziamento sulla base di bando competitivo: Federal Ministry of Education and Research, Grant number 01KG1109, Germany.

2011 - Systematic Review of Meta-Analyses on the Efficacy of SSRI and SNRI in the Treatment of Major Depression. Ammesso al finanziamento sulla base di bando competitivo: Federal Ministry of Education and Research, Grant number 01KG0722, Germany.

2011 - Agreement for Performance of Work, World Health Organisation (WHO): To assist the WHO Secretariat in updating the mhGAP Evidence Resource Centre, within WHO mental health Gap Action Programme (mhGAP). WHO Geneva Switzerland. WHO Registration 2011/182038-0.

2013 - European Commission - Marie Curie International Outgoing Fellowship: 626466 CHILD TRAUMA IN LMIC FP7-PEOPLE-2013-IOF.

2014 - Agreement for Performance of Work, World Health Organisation (WHO): To assist WHO secretariat in updating mhGAP Evidence Resource Centre and Guidelines. WHO Geneva Switzerland. WHO Registration 2014/409411-0.

2014 - Agreement for Performance of Work, World Health Organisation (WHO): To assist WHO secretariat in developing the ETAT guidelines. WHO Geneva Switzerland. WHO Registration 2014/454490-0.